Immunologic tolerance maintained by CD25+ CD4+ regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance - PubMed (original) (raw)
Review
Immunologic tolerance maintained by CD25+ CD4+ regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance
S Sakaguchi et al. Immunol Rev. 2001 Aug.
Abstract
There is accumulating evidence that T-cell-mediated dominant control of self-reactive T-cells contributes to the maintenance of immunologic self-tolerance and its alteration can cause autoimmune disease. Efforts to delineate such a regulatory T-cell population have revealed that CD25+ cells in the CD4+ population in normal naive animals bear the ability to prevent autoimmune disease in vivo and, upon antigenic stimulation, suppress the activation/proliferation of other T cells in vitro. The CD25+ CD4+ regulatory T cells, which are naturally anergic and suppressive, appear to be produced by the normal thymus as a functionally distinct subpopulation of T cells. They play critical roles not only in preventing autoimmunity but also in controlling tumor immunity and transplantation tolerance.
Similar articles
- Thymus and autoimmunity: production of CD25+CD4+ naturally anergic and suppressive T cells as a key function of the thymus in maintaining immunologic self-tolerance.
Itoh M, Takahashi T, Sakaguchi N, Kuniyasu Y, Shimizu J, Otsuka F, Sakaguchi S. Itoh M, et al. J Immunol. 1999 May 1;162(9):5317-26. J Immunol. 1999. PMID: 10228007 - The role of regulatory T cells in controlling immunologic self-tolerance.
Takahashi T, Sakaguchi S. Takahashi T, et al. Int Rev Cytol. 2003;225:1-32. doi: 10.1016/s0074-7696(05)25001-5. Int Rev Cytol. 2003. PMID: 12696589 Review. - Naturally arising CD25+CD4+ regulatory T cells in maintaining immunologic self-tolerance and preventing autoimmune disease.
Takahashi T, Sakaguchi S. Takahashi T, et al. Curr Mol Med. 2003 Dec;3(8):693-706. doi: 10.2174/1566524033479429. Curr Mol Med. 2003. PMID: 14682491 Review. - Naturally anergic and suppressive CD25(+)CD4(+) T cells as a functionally and phenotypically distinct immunoregulatory T cell subpopulation.
Kuniyasu Y, Takahashi T, Itoh M, Shimizu J, Toda G, Sakaguchi S. Kuniyasu Y, et al. Int Immunol. 2000 Aug;12(8):1145-55. doi: 10.1093/intimm/12.8.1145. Int Immunol. 2000. PMID: 10917889 - Human CD4(+)CD25(+) thymocytes and peripheral T cells have immune suppressive activity in vitro.
Stephens LA, Mottet C, Mason D, Powrie F. Stephens LA, et al. Eur J Immunol. 2001 Apr;31(4):1247-54. doi: 10.1002/1521-4141(200104)31:4<1247::aid-immu1247>3.0.co;2-m. Eur J Immunol. 2001. PMID: 11298351
Cited by
- Nanoparticles in Periodontitis Therapy: A Review of the Current Situation.
Wang D, Li Q, Xiao C, Wang H, Dong S. Wang D, et al. Int J Nanomedicine. 2024 Jul 9;19:6857-6893. doi: 10.2147/IJN.S465089. eCollection 2024. Int J Nanomedicine. 2024. PMID: 39005956 Free PMC article. Review. - FOXP3 full length splice variant is associated with kidney allograft tolerance.
Saleh QW, Mohammadnejad A, Tepel M. Saleh QW, et al. Front Immunol. 2024 Apr 10;15:1389105. doi: 10.3389/fimmu.2024.1389105. eCollection 2024. Front Immunol. 2024. PMID: 38660296 Free PMC article. - Intragraft memory-like CD127hiCD4+Foxp3+ Tregs maintain transplant tolerance.
Zhao Y, Nicholson L, Wang H, Qian YW, Hawthorne WJ, Jimenez-Vera E, Gloss BS, Lai J, Thomas A, Chew YV, Burns H, Zhang GY, Wang YM, Rogers NM, Zheng G, Yi S, Alexander SI, O'Connell PJ, Hu M. Zhao Y, et al. JCI Insight. 2024 Feb 13;9(6):e169119. doi: 10.1172/jci.insight.169119. JCI Insight. 2024. PMID: 38516885 Free PMC article. - Cross-talk between disulfidptosis and immune check point genes defines the tumor microenvironment for the prediction of prognosis and immunotherapies in glioblastoma.
Zhou Y, Qin X, Hu Q, Qin S, Xu R, Gu K, Lu H. Zhou Y, et al. Sci Rep. 2024 Feb 16;14(1):3901. doi: 10.1038/s41598-024-52128-x. Sci Rep. 2024. PMID: 38365809 Free PMC article. - Drug resistance in glioblastoma: from chemo- to immunotherapy.
Sharma S, Chepurna O, Sun T. Sharma S, et al. Cancer Drug Resist. 2023 Oct 11;6(4):688-708. doi: 10.20517/cdr.2023.82. eCollection 2023. Cancer Drug Resist. 2023. PMID: 38239396 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials